COVID profilaxis - overview (cold, infection, doctor, prescription)

[ukrkoz]

Note: Patients are asked to consult a doctor.


Treatment protocol

Prophylaxis

1. Zinc (25mg to 50mg per day)
2. Quercetin (250mg to 500mg per day)
3. Bromhexine (25mg to 50mg per day)
4. Vitamin D (2000 IU per day)
5. Vitamin C (1000mg per day)

Early treatment

1. Zinc (75mg to 150mg per day)
2. Quercetin (500mg to 1000mg per day)
3. Bromhexine (50mg to 100mg per day)
4. Vitamins D (5000 u/d) and C (1000mg/d)
5. Aspirin (162mg to 325mg per day)*

Prescription only

1. Ivermectin (0.2 mg/kg daily for two days)*
2. High-dose vitamin D (up to 100,000 IU)
3. Azithromycin (up to 500mg per day)
4. Prednisone (60mg to 80mg per day)*
5. Hydroxychloroquine (400mg per day)*

Notes: Contraindications for aspirin must be observed. Ivermectin may also be used prophylactically on a monthly basis. Prednisone is to be used if pulmonary symptoms develop. Correctly dosed HCQ has been shown to be effective and safe for the early treatment of covid-19.

References

General

• FLCCC Covid-19 Prophylaxis and Treatment Protocols (FLCCC, November 2020)
• EVMS Critical Care Covid-19 Management Protocol (Paul Marik, MD, June 2020)
• Early Outpatient Treatment of COVID-19 (McCullough et al., AmJM, October 2020)

Ivermectin

1. Overview: A summary of international ivermectin covid studies (c19ivermectin.com)
2. Review: Ivermectin – A Potential Global Solution to the Covid-19 Pandemic (FLCCC)
3. Review: Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 (FLCCC, November 2020)

Zinc

1. Study: Low zinc levels at clinical admission associates with poor outcomes in COVID-19 (Vogel et al., medRxiv, October 2020)
2. Study: Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients (Carlucci et al., MedRxiv, May 2020)
3. Study: Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients (Eric Finzi, International Journal of Infectious Diseases, June 2020)
4. Study: Zinc Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture (Velthuis et al, PLOS Path, 2010)
5. Study: Effect of Zinc Salts on Respiratory Syncytial Virus Replication (Suara & Crowe, AAC, 2004)
6. Study: Zinc for the common cold (Cochrane Systematic Review, 2013)
7. Review: Zinc supplementation to improve treatment outcomes among children diagnosed with respiratory infections (WHO, Technical Report, 2011)
8. Article: Can Zinc Lozenges Help with Coronavirus Infections? (McGill University, March 2020)

Quercetin

1. Study: Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells (Ling Yi et al., Journal of Virology, 2004)
2. Study: Zinc Ionophore Activity of Quercetin and Epigallocatechin-gallate: From Hepa 1-6 Cells to a Liposome Model (Dabbagh et al., JAFC, 2014)
3. Study: Quercetin as an Antiviral Agent Inhibits Influenza A Virus Entry (Wu et al, Viruses, 2016)
4. Study: Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (Biancatelli et al, Front. in Immun., June 2020)
5. Report: EVMS Critical Care Covid-19 Management Protocol (Paul Marik, MD, June 2020)

Bromhexine

1. Study: TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections (Wen Shen et al., Biochimie Journal, 2017)
2. Letter: Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection (Maggio and Corsini, Pharmacological Research, April 2020)
3. Study: Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? (Depfenhart et al., Internal and Emergency Medicine, May 2020)
4. Study: Bromhexine Hydrochloride: Potential Approach to Prevent or Treat Early Stage COVID-19 (Stepanov and Lierz, Journal of Infectious Diseases and Epidemiology, June 2020)
5. Study: TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19 (Arsalan Azimi, Drug Target Review, June 2020)
6. Trial: Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial (Ansarin et al., BioImpacts, July 2020)

Aspirin and heparin

1. Study: Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy (Tang et al, JTH, May 2020)
2. Study: Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 (Wichmann et al., Annals of Internal Medicine, May 2020)
3. Review: Anticoagulation Guidance Emerging for Severe COVID-19 (Medpage Today)
4. Study: Platelet gene expression and function in patients with COVID-19 (Manne et al., ASH Blood, September 2020)
5. Review: Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? (Hussein et al., Medical Hypotheses, November 2020)

https://swprs.org/on-the-treatment-of-covid-19/

[Rom623]

Great post !

-I would add a multivitamin like naturelo 1 a day that also has selenium and k2.
-Melatonin also proving to be really helpful, also part of Dr. Mariks Math+ protocol


Dr. Zalenko's latest clinical trial showing 84% fewer hospitalizations with early treatment of HCQ + zinc + azithromycin. Somehow others have managed to missed this data point.


There are some doctors who believe in more than telling you call if symptoms worsen(outpatient care), see the bottom of this page.